Lung Cancer News and Research

Latest Lung Cancer News and Research

Synta Pharmaceuticals to present posters on STA-9090 and elesclomol at AACR 2010

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that Synta will present multiple posters at the American Association for Cancer Research 101st Annual Meeting 2010 to be held April 17-21, 2010 in Washington, DC.

8 Apr 2010

Researchers find new genomic approach to identify smokers at risk of lung cancer

Researchers from Boston University School of Medicine in collaboration with investigators at the University of Utah, have discovered a new approach for identifying smokers at the highest risk for developing lung cancer. The findings, which appear in the April 7th issue of Science Translational Medicine, will allow the researchers to use a genomic approach to prevent lung cancer in these individuals and to personalize cancer chemoprophylaxis and therapy.

8 Apr 2010

Phase II clinical trial of Avastin and Tarceva in patients with glioblastoma multiforme

Patients suffering from recently diagnosed malignant brain tumors called glioblastoma multiforme or a rare variant called gliosarcoma may be eligible to participate in a Phase II clinical trial at Cedars-Sinai Medical Center that combines two innovative drugs.

8 Apr 2010

Accumetrics completes enrollment phase of GRAVITAS clinical trial

Accumetrics, Inc., a privately-held developer and marketer of the VerifyNow® System, the first rapid and easy to use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, announced that it has completed the enrollment phase of its landmark clinical trial, GRAVITAS.

7 Apr 2010

Study: Carbon nanotubes degraded by MPO enzyme induce less inflammation

A team of Swedish and American scientists has shown for the first time that carbon nanotubes can be broken down by an enzyme - myeloperoxidase (MPO) - found in white blood cells.

6 Apr 2010

Rosetta Genomics' Philadelphia lab commences FNA cell block sample analysis with miRview squamous test

Rosetta Genomics, Ltd., a leading developer and provider of microRNA-based molecular diagnostics, announced today that starting April 1, 2010 physicians are able to send FNA cell block samples to Rosetta Genomics' CLIA-certified and CAP-accredited laboratory in Philadelphia for analysis using Rosetta's miRview squamous test. FNA is a less invasive method to obtain tumor cells compared with tumor resections or biopsies.

5 Apr 2010

Scientists show carbon nanotubes can be broken down by MPO

A team of Swedish and American scientists has shown for the first time that carbon nanotubes can be broken down by an enzyme - myeloperoxidase - found in white blood cells. Their discoveries are presented in Nature Nanotechnology and contradict what was previously believed, that carbon nanotubes are not broken down in the body or in nature.

5 Apr 2010

NHS cancer patients to receive latest and best treatments available

Cancer patients on the National Health Service may soon be offered expensive life extending drugs which are currently denied to them. David Cameron has proposed on behalf of the Conservatives that the drugs that are licensed and prescribed by the health consultant of the patient should be made available to the cancer patient, irrespective of the NHS rationing.

5 Apr 2010

Cancer research at Georgia Tech: Report

Cancer treatment typically involves surgery, radiation therapy, chemotherapy, hormone therapy or biological therapy. An oncologist may use one therapy or a combination of methods, depending on the type and location of the cancer, whether the disease has spread, the patient's age and general health, and other factors.

3 Apr 2010

CTRC commences enrollment in Phase 2 trial of REOLYSIN combination for SCC lung cancer

A virus that destroys cancer cells but leaves normal cells unharmed may offer hope to those affected by squamous cell carcinoma of the lungs (SCC lung cancer), according to investigators from the Cancer Therapy & Research Center (CTRC) at the University of Texas Health Science Center at San Antonio. The CTRC has started patient enrollment in a US Phase 2 clinical trial using intravenous administration of REOLYSIN® in combination with carboplatin and paclitaxel in patients with SCC lung cancer.

3 Apr 2010

Cyclacel Pharmaceuticals' abstracts on cell cycle inhibitor drugs selected for presentation at AACR meeting

Cyclacel Pharmaceuticals, Inc. today announced that six abstracts highlighting translational and preclinical data for Cyclacel's cell cycle inhibitor drugs have been selected for presentation at the American Association of Cancer Research (AACR) Annual Meeting, being held from April 17-21, 2010, in Washington, DC.

2 Apr 2010

SBRT effective in primary tumor control, study finds

Many of the world's leading radiation oncologists are employing the unique capabilities of SBRT to treat a variety of cancers that often have defied conventional radiation therapy techniques. A multitude of studies evaluating SBRT are ongoing and investigators are publishing articles that demonstrate the effectiveness of this technique. Two studies led by renowned radiation oncologists were conducted at centers that use Elekta SBRT technology, and their results were published recently.

From Elekta 2 Apr 2010

Study reveals less invasive procedure beneficial for patients with sufficient lung function

Research published in the April edition of the Journal of Thoracic Oncology sought to compare the outcomes of a sleeve lobectomy and a pneumonectomy procedure, in order to determine which is a more acceptable standard treatment for patients with non-small cell lung cancer.

2 Apr 2010

Study promises new combination cancer therapy for drug resistance

Results reported in the April 2nd issue of the journal Cell, a Cell Press publication, reveal a new source for the drug resistance that crops up all too often and quickly in the tumors of cancer patients undergoing therapy.

2 Apr 2010

UK NICE recommends Eli Lilly's ALIMTA as maintenance therapy for nonsquamous NSCLC

Eli Lilly and Company announced today that its chemotherapy ALIMTA® (pemetrexed for injection) received a positive "Final Appraisal Determination" from the United Kingdom's National Institute for Health and Clinical Excellence (NICE).

2 Apr 2010

International, four-year study finds dutasteride reduces risk of prostate cancer diagnosis in men

A drug already prescribed to shrink benign, enlarged prostates has been shown to reduce the risk of a prostate cancer diagnosis by 23 percent in men with an increased risk of the disease, a large international trial has found. Results are reported April 1 in the New England Journal of Medicine.

2 Apr 2010

ImmunoCellular Therapeutics files Annual Report with Securities and Exchange Commission for 2009

ImmunoCellular Therapeutics announced today that it has filed its Annual Report with the Securities and Exchange Commission for the period ended December 31, 2009 on Form 10-K.

1 Apr 2010

BeaconEquity.com announces investment report featuring OXiGENE

BeaconEquity.com announces an investment report featuring OXiGENE Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

1 Apr 2010

Four studies of bavituximab and PS-targeting antibodies to be presented at AACR 2010

Peregrine Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing innovative monoclonal antibodies for the treatment of cancer and viral infections, today announced four studies of bavituximab and its other PS-targeting antibodies have been accepted for presentation at the 101st Annual Meeting of the American Association for Cancer Research to be held April 17-21, 2010 in Washington, D.C.

1 Apr 2010

Rosetta Genomics reports revenues of $150,000 for full-year 2009

Rosetta Genomics, Ltd., a leading developer of microRNA-based molecular diagnostics, today reported that on March 26, 2010 the Company filed its Form 20-F with the U.S. Securities and Exchange Committee, which contains financial results for the three and 12 months ended December 31, 2009.

31 Mar 2010

Lung Cancer News and Research

Latest Lung Cancer News and Research

Synta Pharmaceuticals to present posters on STA-9090 and elesclomol at AACR 2010

Researchers find new genomic approach to identify smokers at risk of lung cancer

Phase II clinical trial of Avastin and Tarceva in patients with glioblastoma multiforme

Accumetrics completes enrollment phase of GRAVITAS clinical trial

Study: Carbon nanotubes degraded by MPO enzyme induce less inflammation

Rosetta Genomics' Philadelphia lab commences FNA cell block sample analysis with miRview squamous test

Scientists show carbon nanotubes can be broken down by MPO

NHS cancer patients to receive latest and best treatments available

Cancer research at Georgia Tech: Report

CTRC commences enrollment in Phase 2 trial of REOLYSIN combination for SCC lung cancer

Cyclacel Pharmaceuticals' abstracts on cell cycle inhibitor drugs selected for presentation at AACR meeting

SBRT effective in primary tumor control, study finds

Study reveals less invasive procedure beneficial for patients with sufficient lung function

Study promises new combination cancer therapy for drug resistance

UK NICE recommends Eli Lilly's ALIMTA as maintenance therapy for nonsquamous NSCLC

International, four-year study finds dutasteride reduces risk of prostate cancer diagnosis in men

ImmunoCellular Therapeutics files Annual Report with Securities and Exchange Commission for 2009

BeaconEquity.com announces investment report featuring OXiGENE

Four studies of bavituximab and PS-targeting antibodies to be presented at AACR 2010

Rosetta Genomics reports revenues of $150,000 for full-year 2009

The ultimate guide to lung research tools and protocols eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Lung Cancer News and Research

Latest Lung Cancer News and Research

The ultimate guide to lung research tools and protocols eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in